Labcorp nabs FDA green light for BRAF melanoma diagnostic August 10, 2026Posted inMedical Technology The FDA has signed off on Labcorp’s companion diagnostic for patients with advanced melanoma carrying certain BRAF variants. Post navigation Previous Post FDA issues alert in wake of BD recall of faulty needle sets that caused four deathsNext PostAbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
